Neuronetics, Inc.: Madryn Asset Management, LP amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Madryn Asset Management amended its Schedule 13D filing on Neuronetics, disclosing a change to its beneficial ownership stake in the medical device maker. The filing, submitted under SEC accession number 0001193125-26-464271, updates the investment firm's previously reported position. Schedule 13D amendments are required when a holder's ownership or intent shifts materially, making the disclosure a signal of potential activist or strategic interest. Investors will watch for further filings to gauge whether Madryn is building, trimming or holding its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Madryn Asset Management, LP, Neuronetics, Inc.